Literature DB >> 18046301

Progress in global measles control and mortality reduction, 2000-2006.

.   

Abstract

The World Health Organization (WHO) and United Nations Children's Fund (UNICEF) comprehensive strategy for measles mortality reduction is focused on 47 priority countries. Components include 1) achieving and maintaining high coverage (>90%) with the first dose of measles vaccine by age 12 months in every district of each priority country through routine immunization services; 2) ensuring that all children receive a second opportunity for measles vaccination; 3) maintaining effective case-based surveillance and monitoring of vaccination coverage; and 4) providing appropriate clinical management, including vitamin A supplementation. In 2005, the World Health Assembly set a goal for global measles control as part of the Global Immunization Vision and Strategy (GIVS): a 90% reduction in measles mortality by 2010, compared with 2000 levels. In January 2007, WHO/UNICEF reported that implementation of measles mortality reduction strategies had reduced measles mortality by 60%, from an estimated 873,000 deaths in 1999 to 345,000 deaths in 2005. This reduction exceeded the goal of 50% measles mortality reduction by 2005 (compared with 1999 levels) that had been set in 2002. This report updates previous reports by detailing 1) measles mortality reduction activities implemented during 2006 and 2) the impact of activities since 2000 on the global burden of measles and progress toward the GIVS mortality reduction goal for 2010.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046301

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  9 in total

1.  A long-lasting measles epidemic in Maroua, Cameroon 2008-2009: mass vaccination as response to the epidemic.

Authors:  Francisco J Luquero; Heloise Pham-Orsetti; D A T Cummings; Philippe E Ngaunji; Marcelino Nimpa; Florence Fermon; Ndong Ngoe; Stephen Sosler; Peter Strebel; Rebecca F Grais
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

2.  A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.

Authors:  Chien-Hsiung Pan; Catherine E Greer; Debra Hauer; Harold S Legg; Eun-Young Lee; M Jeff Bergen; Brandyn Lau; Robert J Adams; John M Polo; Diane E Griffin
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

3.  Trends in immunization completion and disparities in the context of health reforms: the case study of Tanzania.

Authors:  Innocent A Semali
Journal:  BMC Health Serv Res       Date:  2010-10-30       Impact factor: 2.655

4.  Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.

Authors:  Chien-Hsiung Pan; Gretchen S Jimenez; Nitya Nair; Qun Wei; Robert J Adams; Fernando P Polack; Alain Rolland; Adrián Vilalta; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

5.  Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.

Authors:  Wen-Hsuan W Lin; Adrian Vilalta; Robert J Adams; Alain Rolland; Sean M Sullivan; Diane E Griffin
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

6.  Aldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations.

Authors:  R Yasmeen; J M Meyers; C E Alvarez; J L Thomas; A Bonnegarde-Bernard; H Alder; T L Papenfuss; D M Benson; P N Boyaka; O Ziouzenkova
Journal:  Biochim Biophys Acta       Date:  2013-09-27

Review 7.  Vaccine chronicle in Japan.

Authors:  Tetsuo Nakayama
Journal:  J Infect Chemother       Date:  2013-07-09       Impact factor: 2.211

8.  Measles outbreak response immunization is context-specific: insight from the recent experience of Médecins Sans Frontières.

Authors:  Andrea Minetti; Cameron Bopp; Florence Fermon; Gwenola François; Rebecca F Grais; Lise Grout; Northan Hurtado; Francisco J Luquero; Klaudia Porten; Laurent Sury; Meguerditch Terzian
Journal:  PLoS Med       Date:  2013-11-05       Impact factor: 11.069

Review 9.  The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines.

Authors:  Darren Z L Mok; Kuan Rong Chan
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.